Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. - Wikidata - wikimedia - TriplyDB

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

http://www.wikidata.org/entity/Q46190981

about

Dopamine agonists for hyperprolactinaemia Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A Review The risks of overlooking the diagnosis of secreting pituitary adenomas Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results.Pituitary incidentaloma: an endocrine society clinical practice guideline.Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.Hyperprolactinaemia - a problem in patients from the reproductive period to the menopause.Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach.Lactation associated with a pituitary tumour in a man.The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage Management of macroprolactinomas.Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.Combined high-field intraoperative magnetic resonance imaging and endoscopy increase extent of resection and progression-free survival for pituitary adenomas.Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin.New insights in the management of antipsychotics in the treatment of schizophrenia in a patient with prolactinoma: a case report and review of the literature Early prediction of long-term response to cabergoline in patients with macroprolactinomas ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.Characteristics of dynamic magnetic resonance image enhancement in prolactinomas resistant to dopamine agonist therapy.Treatment of prolactinomas in low-income countries.Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.Cabergoline plus metformin therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinemia.Endocrinological outcomes of pure endoscopic transsphenoidal surgery: a Croatian Referral Pituitary Center experience Effect of dopaminergic drug treatment on surgical findings in prolactinomas.Ultrafiltration - an alternative method to polyethylene glycol precipitation for macroprolactin detection.A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case report Treatment of hyperprolactinemia: a systematic review and meta-analysis.The prevalence of hyperprolactinemia in non-functioning pituitary macroadenomas.Establishing reference intervals for sex hormones on the analytical platforms Advia Centaur and Immulite 2000XP.A novel surgical approach for the management of giant invasive prolactinoma compressing the brainstem Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline.Diagnostic Accuracy of Perioperative Measurement of Basal Anterior Pituitary and Target Gland Hormones in Predicting Adrenal Insufficiency After Pituitary Surgery Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands Effects of preoperative bromocriptine treatment on prolactin-secreting pituitary adenoma surgery.A unique case of Turner syndrome accompanying prolactinoma and unexpected elongated styloid process: Clinical and cone-beam computed tomographic features Pregnancy in multiple endocrine neoplasia type 1 equals multiple complications Aripiprazole use combined with depot antipsychotic medication: two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital.Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.Heregulin regulates prolactinoma gene expression.Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy

P2860

Q24201524-CD64026E-F452-415A-8170-21839C70A110 Q26739267-6C134663-7085-4D3C-9789-3A7045CB6748 Q28076665-3545A053-BD6A-46F4-99F9-0809613C50AC Q30299965-8DEA7626-7F87-4C27-BA80-DC0D70C3487E Q30353104-9B1C457A-F2C3-4309-BC00-5DC24C38D404 Q33680681-9C76F892-17B8-41C5-BFC1-832D71D886F9 Q33704842-2D0A6BBD-036A-434E-A88A-9207A43D6CDF Q33721266-19D73DD3-56E4-4FFB-A8AE-E7680D1623C7 Q33753848-44F1EA05-CBA7-4022-839F-611F975BCEED Q33770763-7A993A8D-40B1-448F-81D6-BEB93E8DFE70 Q33792371-4342DC07-460E-4F83-B32C-E7560737F7CD Q33943570-49BD45D2-07D2-4ADE-AD47-27E2316AD473 Q34167819-67335044-38BD-4957-AC70-2761B834483C Q34211804-5576CC5F-6BBB-4095-ADDE-DF1F890D3D18 Q34296291-3C02B340-4014-4FE8-AB4F-7C2735EEC73C Q34318860-5D30B9FC-1FA5-470F-82C4-B180A5595452 Q34745279-4EE5447F-B20E-4DA8-A41A-BD30DCF32432 Q34942996-B2CB7C89-2D94-4AD2-B5E7-86CCCDC6FFF5 Q35106933-55C8AA25-0BF5-4F55-ADC5-1BE4941DEF14 Q35109902-E5D42C06-519E-4981-8DFA-59F2601B244C Q35137687-7C5D7AF6-AF69-493C-9A17-F954D5572A01 Q35589236-EA833296-1D79-42E4-A1EF-72DEF83FFA98 Q36011347-2A7DE7C9-9967-4FE6-A60E-74E799DB8C2F Q36182003-543E8C77-A461-4568-B1FE-25E79252BA21 Q36220645-E4563A8F-E281-4BF1-8E70-250D5E0BA82F Q36322256-69608169-D4BA-4068-A61D-BB56BB199EA3 Q36355322-B49407C8-65F4-453C-8924-66CC47037BDA Q36412084-1D78200F-DC5F-4C0D-B0F5-CBABF4E61312 Q36419694-63DA5ECE-D0D1-4D8B-8445-99ABCDB79EE0 Q36427494-14782AAB-92B9-4D75-8E3C-CF2F9041DC94 Q36629594-465ABF66-FE9C-48E2-9C41-DABBAA82BC9B Q36663948-C548CDE4-BA7B-4C9C-8C20-6FF984A23F79 Q36813498-E1561AFC-A5AB-490A-BAEB-56B24DB85FCB Q36824494-D75CAF6C-A1C8-4D35-85BF-281CF3B6E9F9 Q36951783-1B3A8B0A-AD70-4F21-AB8C-0C6C0E5AE539 Q37070365-91AC8E86-3A85-4686-B9C0-DA4B60A716DF Q37078928-6C46B9FA-BCA0-42B3-B5CD-DA0B1E0E81C9 Q37162791-64C2D445-E4C2-4759-B36F-BDF1AEE3C277 Q37208143-BEC36AAB-CF62-4695-BD47-C0C843DF1043 Q37257610-948C21B4-4A69-4B8F-8BFB-918CD69AC1BA

P2860

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

http://www.wikidata.org/entity/Q46190981

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

@en

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

@nl

type

label

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

@en

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

@nl

prefLabel

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

@en

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

@nl

P1433

Q46190981-9F7A3954-4ED3-43C3-BE6F-208F50B86C95

P1476

Q46190981-C824B6A3-A230-4AAB-AB86-04016D82CF07

P2093

Q46190981-4519A3E4-E81A-4CAD-8A65-8A0782FA5F59

Q46190981-4DC26A84-E1F5-4115-A057-89CC69688AEC

Q46190981-4EBE41B2-8F67-43BA-A172-DD97D5BC4E84

Q46190981-6E6952B7-78DF-4557-A769-6F82254389FB

Q46190981-7685EAF9-19E3-4557-AEE9-93CFE1502484

Q46190981-8C1302E2-2D7C-4030-B547-DC2062916B07

Q46190981-8CCD87ED-F266-46C7-9472-7B0D53BC8F8E

Q46190981-8EED1F46-8AC0-465B-AC7D-2D8D87C4553A

Q46190981-95629940-D653-4C83-848C-6E18534FB0C2

Q46190981-A0001397-1B3F-4DE7-BA07-FDCB27839714

P2860

Q46190981-0DF28DAF-1E9F-42D6-919B-5179AD5133AF

Q46190981-0EBF08BA-20BC-4DB9-963B-B2E8A03F2168

Q46190981-0F86E7BB-5791-4500-9D38-4F9914B9061F

Q46190981-15B19865-3437-4676-8814-B692A1DE4D6C

Q46190981-3919F878-B881-4E5E-83AF-78A5ED7B7E0F

Q46190981-3F1F393A-6C0D-4129-A833-AFD1C52B0DAD

Q46190981-40D7D06B-C623-4899-8CF4-F71A51CEA9E9

Q46190981-4210B8BE-3587-4A70-9A9A-C6B530CDCF3D

Q46190981-43942A6E-6B4C-4DA5-BD0B-D96DB2F82852

Q46190981-4AB37627-6EDA-4BB3-A959-190F7ADC9027

P304

Q46190981-688518F1-1C41-4DF5-B4CF-F102B8B446D9

P31

Q46190981-048812DB-44AB-4EDF-93ED-79952F216A61

P356

Q46190981-BF69647B-46A3-4E84-9F67-D48BF2BE6F33

P433

Q46190981-0381A81A-8698-45E4-B2CB-533CE2934832

P478

Q46190981-ACF51495-F442-4ED1-B11C-E987150CBE4F

P50

Q46190981-4F00D934-6AFD-4655-9101-62152A5A4A6D

Q46190981-96F1743C-4611-4C96-8DFA-A384D763B106

Q46190981-B04ACD8B-5EAA-4600-8649-D1CE63B18D11

Q46190981-B30CB7A4-CC5D-49D1-8B0A-DA10E5D5B8AA

Q46190981-C137D8D0-C5F3-421C-A716-2EC822D667FA

P577

Q46190981-64BBCD07-944A-4FF5-9294-44C8B6C99592

P5875

Q46190981-58C36F6A-D3DA-4331-B16A-42740FA9ACE0

P698

Q46190981-D07993B6-A761-4A6E-891B-625E84F4FB02

P356

J.1365-2265.2006.02562.X

P1433

Clinical Endocrinology

P1476

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

@en

P2093

Andrea Giustina

http://www.w3.org/2001/XMLSchema#string

David Kleinberg

http://www.w3.org/2001/XMLSchema#string

Edward Laws

http://www.w3.org/2001/XMLSchema#string

Felipe F Casanueva

http://www.w3.org/2001/XMLSchema#string

Hugo Fideleff

http://www.w3.org/2001/XMLSchema#string

John A H Wass

http://www.w3.org/2001/XMLSchema#string

Luis G Sobrinho

http://www.w3.org/2001/XMLSchema#string

Marcello D Bronstein

http://www.w3.org/2001/XMLSchema#string

Mark E Molitch

http://www.w3.org/2001/XMLSchema#string

Maurice Scanlon

http://www.w3.org/2001/XMLSchema#string

P2860

Current approaches to imaging of the sellar region and pituitary.

Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.

Criteria for cure of acromegaly: a consensus statement.

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.

Clinical practice. Prolactinoma.

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

Clinical review 136: Primary lymphoma of the pituitary: an emerging clinical entity.

Current management of prolactinomas.

Hyperprolactinemia: pathophysiology and management.

Medical management of prolactin-secreting pituitary adenomas.

P304

265-273

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2265.2006.02562.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Cappabianca

Janet A Schlechte

Annamaria Colao

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6899790

http://www.w3.org/2001/XMLSchema#string

P698

16886971

http://www.w3.org/2001/XMLSchema#string